Citation Impact
Citing Papers
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
2010 Standout
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
2015
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma
2011
Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors
2018
A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma
2013
A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer
2014
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
2015 Standout
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
2009 Standout
Cancer-related inflammation and treatment effectiveness
2014 Standout
Renal cell carcinoma
2017 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
RECIST revisited: A review of validation studies on tumour assessment
2006
Systemic Therapy for Metastatic Renal-Cell Carcinoma
2017
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
2009 Standout
Antiangiogenesis beyond VEGF inhibition: A journey from antiangiogenic single-target to broad-spectrum agents
2013
The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer.
2017 StandoutNobel
Targeted therapy for advanced renal cell carcinoma
2008
Works of Ellen Blanc being referenced
Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.
2012
Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
2017
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
2011
Different measurement criteria give different tumor response classifications in patients with metastatic renal cancer (MRCC)
2004
Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial.
2010